PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Both companies show declining cash positions (-10.40% vs RVPH's -60.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Below half of RVPH's -60.75%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of RVPH's 13.45%. David Dodd sees a leaner approach to short-term items.
-10.80%
Below half of RVPH's -57.38%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.91%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-8.44%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Below half of RVPH's -54.35%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
1.1-1.25x RVPH's -12.38%. Bill Ackman wonders if the firm is incurring more one-time charges than competitor.
-12.74%
50-75% of RVPH's -21.18%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Less than half of RVPH's -68.75%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Less than half of RVPH's -21.47%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
Similar yoy to RVPH's -3.92%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
Below half RVPH's -648.88%. Michael Burry sees potential underperformance in building shareholder capital.
-10.73%
Below half RVPH's -54.35%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Less than half of RVPH's -51.04%. David Dodd sees less overall debt expansion vs. competitor.
10.43%
Less than half of RVPH's 61.09%. David Dodd sees better deleveraging or stronger cash buildup than competitor.